Top

Published in:

Open Access 13-03-2024 | Antibiotic | Original

Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis

Authors: Ming G. Chai, Quyen Tu, Menino O. Cotta, Michelle J. Bauer, Ross Balch, Charles Okafor, Tracy Comans, Peter Kruger, Jason Meyer, Kiran Shekar, Kara Brady, Cheryl Fourie, Natalie Sharp, Luminita Vlad, David Whiley, Jacobus P. J. Ungerer, Brett C. Mcwhinney, Andras Farkas, David L. Paterson, Julia E. Clark, Krispin Hajkowicz, Sainath Raman, Seweryn Bialasiewicz, Jeffrey Lipman, Brian M. Forde, Patrick N. A. Harris, Luregn J. Schlapbach, Lachlan Coin, Jason A. Roberts, Adam D. Irwin

Published in: Intensive Care Medicine | Issue 4/2024

Abstract

Purpose

Early recognition and effective treatment of sepsis improves outcomes in critically ill patients. However, antibiotic exposures are frequently suboptimal in the intensive care unit (ICU) setting. We describe the feasibility of the Bayesian dosing software Individually Designed Optimum Dosing Strategies (ID-ODS™), to reduce time to effective antibiotic exposure in children and adults with sepsis in ICU.

Methods

A multi-centre prospective, non-randomised interventional trial in three adult ICUs and one paediatric ICU. In a pre-intervention Phase 1, we measured the time to target antibiotic exposure in participants. In Phase 2, antibiotic dosing recommendations were made using ID-ODS™, and time to target antibiotic concentrations were compared to patients in Phase 1 (a pre–post-design).

Results

175 antibiotic courses (Phase 1 = 123, Phase 2 = 52) were analysed from 156 participants. Across all patients, there was no difference in the time to achieve target exposures (8.7 h vs 14.3 h in Phase 1 and Phase 2, respectively, p = 0.45). Sixty-one courses in 54 participants failed to achieve target exposures within 24 h of antibiotic commencement (n = 36 in Phase 1, n = 18 in Phase 2). In these participants, ID-ODS™ was associated with a reduction in time to target antibiotic exposure (96 vs 36.4 h in Phase 1 and Phase 2, respectively, p < 0.01). These patients were less likely to exhibit subtherapeutic antibiotic exposures at 96 h (hazard ratio (HR) 0.02, 95% confidence interval (CI) 0.01–0.05, p < 0.01). There was no difference observed in in-hospital mortality.

Conclusions

Dosing software may reduce the time to achieve target antibiotic exposures. It should be evaluated further in trials to establish its impact on clinical outcomes.

Available only for authorised users

Fleischmann-Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P, Allegranzi B, Reinhart K (2020) Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intens Care Med 46:1552–1562. https://doi.org/10.1007/s00134-020-06151-xCrossRef

Schlapbach LJ, Straney L, Alexander J, MacLaren G, Festa M, Schibler A, Slater A, Group APS (2015) Mortality related to invasive infections, sepsis, and septic shock in critically ill children in Australia and New Zealand, 2002–13: a multicentre retrospective cohort study. Lancet Infect Dis 15:46–54. https://doi.org/10.1016/S1473-3099(14)71003-5CrossRefPubMed

Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, Taiberg L, Osman J, Trenholme G, Opal SM, Goldfarb R, Parrillo JE (2006) The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 193:251–258. https://doi.org/10.1086/498909CrossRefPubMed

Evans IVR, Phillips GS, Alpern ER, Angus DC, Friedrich ME, Kissoon N, Lemeshow S, Levy MM, Parker MM, Terry KM, Watson RS, Weiss SL, Zimmerman J, Seymour CW (2018) Association between the New York sepsis care mandate and in-hospital mortality for pediatric sepsis. JAMA 320:358–367. https://doi.org/10.1001/jama.2018.9071CrossRefPubMedPubMedCentral

Tabak YP, Vankeepuram L, Ye G, Jeffers K, Gupta V, Murray PR (2018) Blood culture turnaround time in U.S. acute care hospitals and implications for laboratory process optimization. J Clin Microbiol. https://doi.org/10.1128/jcm.00500-18CrossRefPubMedPubMedCentral

Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J (2014) DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083. https://doi.org/10.1093/cid/ciu027CrossRefPubMed

Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498–509. https://doi.org/10.1016/s1473-3099(14)70036-2CrossRefPubMedPubMedCentral

Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, McIntyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Moller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47:1181–1247CrossRefPubMedPubMedCentral

Tangden T, Ramos Martin V, Felton TW, Nielsen EI, Marchand S, Bruggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA, Infection Section for the European Society of Intensive Care Medicine tP, Pharmacodynamics Study Group of the European Society of Clinical M, Infectious Diseases tISoA-IP, the Critically Ill Patients Study Group of European Society of Clinical M, Infectious D (2017) The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med 43:1021–1032. https://doi.org/10.1007/s00134-017-4780-6CrossRefPubMed

10.

De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, Leroux-Roels I, Hoste E, Depuydt P, Decruyenaere J, Verstraete AG (2014) Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 40:380–387. https://doi.org/10.1007/s00134-013-3187-2CrossRefPubMed

11.

Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, Timsit JF, Udy AA, Wicha SG, Zeitlinger M, De Waele JJ, Roberts JA, Infection Section of European Society of Intensive Care M, Pharmacokinetic/pharmacodynamic, Critically Ill Patient Study Groups of European Society of Clinical M, Infectious D, Infectious Diseases Group of International Association of Therapeutic Drug M, Clinical T, Infections in the ICU, Sepsis Working Group of International Society of Antimicrobial C (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med 46:1127–1153. https://doi.org/10.1007/s00134-020-06050-1CrossRefPubMedPubMedCentral

12.

Chai MG, Cotta MO, Abdul-Aziz MH, Roberts JA (2020) What are the current approaches to optimising antimicrobial dosing in the intensive care unit? Pharmaceutics 12:638. https://doi.org/10.3390/pharmaceutics12070638CrossRefPubMedPubMedCentral

13.

Jager NGL, Chai MG, van Hest RM, Lipman J, Roberts JA, Cotta MO (2022) Precision dosing software to optimise antimicrobial dosing: a systematic search and follow-up survey of available programs. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2022.03.041CrossRefPubMed

14.

Burton ME, Ash CL, Hill DP Jr, Handy T, Shepherd MD, Vasko MR (1991) A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. Clin Pharmacol Ther 49:685–694. https://doi.org/10.1038/clpt.1991.86CrossRefPubMed

15.

Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, Schumitzky A, Yamada W, Jones B, Minejima E (2018) Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother 62:e02042-e2017. https://doi.org/10.1128/AAC.02042-17CrossRefPubMedPubMedCentral

16.

Zhang Y, Wang TT, Zhang D, You HS, Dong YZ, Liu Y, Du Q, Sun D, Zhang T, Dong YL (2020) Therapeutic drug monitoring coupled with bayesian forecasting could prevent vancomycin-associated nephrotoxicity in renal insufficiency patients: a prospective study and pharmacoeconomic analysis. Therapeutic Drug Monitor 42:600–609. https://doi.org/10.1097/Ftd.0000000000000750CrossRef

17.

Sabourenkov PE, McLeay RC (2019) 1599. AUC24 vancomycin bayesian-based dosing: increasing therapeutic target attainment with decreased TDM cost. Open Forum Infect Dis 6:S583–S583. https://doi.org/10.1093/ofid/ofz360.1463CrossRefPubMedCentral

18.

van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA (1999) Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 21:63–73. https://doi.org/10.1097/00007691-199902000-00010CrossRefPubMed

19.

Irwin AD, Coin LJM, Harris PNA, Cotta MO, Bauer MJ, Buckley C, Balch R, Kruger P, Meyer J, Shekar K, Brady K, Fourie C, Sharp N, Vlad L, Whiley D, Beatson SA, Forde BM, Paterson D, Clark J, Hajkowicz K, Raman S, Bialasiewicz S, Lipman J, Schlapbach LJ, Roberts JA (2021) Optimising treatment outcomes for children and adults through rapid genome sequencing of sepsis pathogens. A study protocol for a prospective, multi-centre trial (DIRECT). Front Cell Infect Microbiol 11:667680. https://doi.org/10.3389/fcimb.2021.667680CrossRefPubMedPubMedCentral

20.

Harris PNA, Bauer MJ, Luftinger L, Beisken S, Forde BM, Balch R, Cotta M, Schlapbach L, Raman S, Shekar K, Kruger P, Lipman J, Bialasiewicz S, Coin L, Roberts JA, Paterson DL, Irwin AD (2024) Rapid nanopore sequencing and predictive susceptibility testing of positive blood cultures from intensive care patients with sepsis. Microbiol Spectr. https://doi.org/10.1128/spectrum.03065-23CrossRefPubMedPubMedCentral

21.

Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA, Group PC (2016) CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ 355:i5239. https://doi.org/10.1136/bmj.i5239CrossRefPubMedPubMedCentral

22.

Lancaster GA, Thabane L (2019) Guidelines for reporting non-randomised pilot and feasibility studies. Pilot Feasibil Stud 5:114. https://doi.org/10.1186/s40814-019-0499-1CrossRef

23.

European Committee on Antimicrobial Susceptibility Testing (2019) Breakpoint tables for interpretation of MICs and zone diameters version 9. In: Editor (ed)^(eds) Book Breakpoint tables for interpretation of MICs and zone diameters version 9. EUCAST, City, pp

24.

Matuschek E, Brown DF, Kahlmeter G (2014) Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect 20:O255–O266. https://doi.org/10.1111/1469-0691.12373CrossRefPubMed

25.

Chai MG, Roberts JA, Farkas A, Cotta MO (2022) Accuracy of a precision dosing software program for predicting antibiotic concentrations in critically ill patients. J Antimicrob Chemother 78:354–358. https://doi.org/10.1093/jac/dkac392CrossRef

26.

Hicks P, Huckson S, Fenney E, Leggett I, Pilcher D, Litton E (2019) The financial cost of intensive care in Australia: a multicentre registry study. Med J Aust 211:324–325. https://doi.org/10.5694/mja2.50309CrossRefPubMed

27.

Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts JA, Pletz MW (2022) Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med 48:311–321. https://doi.org/10.1007/s00134-021-06609-6CrossRefPubMedPubMedCentral

28.

Ewoldt TMJ, Abdulla A, Rietdijk WJR, Muller AE, de Winter BCM, Hunfeld NGM, Purmer IM, van Vliet P, Wils EJ, Haringman J, Draisma A, Rijpstra TA, Karakus A, Gommers D, Endeman H, Koch BCP (2022) Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial. Intensive Care Med. https://doi.org/10.1007/s00134-022-06921-9CrossRefPubMedPubMedCentral

29.

Liebchen U, Briegel J, Brinkmann A, Frey O, Wicha SG (2023) Individualised dosing of antibiotics in ICU patients: timing, target and model selection matter. Intensive Care Med 49:475–476. https://doi.org/10.1007/s00134-023-06990-4CrossRefPubMedPubMedCentral

30.

Greppmair S, Brinkmann A, Roehr A, Frey O, Hagel S, Dorn C, Marsot A, El-Haffaf I, Zoller M, Saller T, Zander J, Schatz LM, Scharf C, Briegel J, Minichmayr IK, Wicha SG, Liebchen U (2023) Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting. Intensive Care Med 49:966–976. https://doi.org/10.1007/s00134-023-07154-0CrossRefPubMedPubMedCentral

31.

Codina MS, Bozkir H, Jorda A, Zeitlinger M (2023) Individualised antimicrobial dose optimisation: a systematic review and meta-analysis of randomised controlled trials. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2023.03.018CrossRefPubMed

32.

Pai Mangalore R, Ashok A, Lee SJ, Romero L, Peel TN, Udy AA, Peleg AY (2022) Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis. Clin Infect Dis 75:1848–1860. https://doi.org/10.1093/cid/ciac506CrossRefPubMedPubMedCentral

33.

Brasier N, Ates HC, Sempionatto JR, Cotta MO, Widmer AF, Eckstein J, Goldhahn J, Roberts JA, Gao W, Dincer C (2023) A three-level model for therapeutic drug monitoring of antimicrobials at the site of infection. Lancet Infect Dis 23:e445–e453. https://doi.org/10.1016/s1473-3099(23)00215-3CrossRefPubMed

34.

Cotta MO, Lipman J, De Waele J (2023) Advancing precision-based antimicrobial dosing in critically ill patients. Intensive Care Med. https://doi.org/10.1007/s00134-022-06969-7CrossRefPubMed

35.

Gershengorn HB, Garland A, Gong MN (2015) Patterns of daily costs differ for medical and surgical intensive care unit patients. Annals Am Thor Soc 12:1831–1836. https://doi.org/10.1513/AnnalsATS.201506-366BCCrossRef

36.

Thompson G, Barker CI, Folgori L, Bielicki JA, Bradley JS, Lutsar I, Sharland M (2017) Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open 7:e016293. https://doi.org/10.1136/bmjopen-2017-016293CrossRefPubMedPubMedCentral

37.

Tanaudommongkon I, John Miyagi S, Green DJ, Burnham JM, van den Anker JN, Park K, Wu J, McCune SK, Yao L, Burckart GJ (2020) Combined pediatric and adult trials submitted to the US food and drug administration 2012–2018. Clin Pharmacol Ther 108:1018–1025. https://doi.org/10.1002/cpt.1886CrossRefPubMed

38.

Edgeworth JD (2023) Respiratory metagenomics: route to routine service. Curr Opin Infect Dis 36:115–123. https://doi.org/10.1097/QCO.0000000000000909CrossRefPubMedPubMedCentral

39.

Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely MN, Hope WW (2014) Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother 58:4094–4102. https://doi.org/10.1128/AAC.02664-14CrossRefPubMedPubMedCentral

40.

Wong G, Farkas A, Sussman R, Daroczi G, Hope WW, Lipman J, Roberts JA (2015) Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. Antimicrob Agents Chemother 59:1411–1417. https://doi.org/10.1128/AAC.04001-14CrossRefPubMedPubMedCentral

Title: Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis
Authors: Ming G. Chai
Quyen Tu
Menino O. Cotta
Michelle J. Bauer
Ross Balch
Charles Okafor
Tracy Comans
Peter Kruger
Jason Meyer
Kiran Shekar
Kara Brady
Cheryl Fourie
Natalie Sharp
Luminita Vlad
David Whiley
Jacobus P. J. Ungerer
Brett C. Mcwhinney
Andras Farkas
David L. Paterson
Julia E. Clark
Krispin Hajkowicz
Sainath Raman
Seweryn Bialasiewicz
Jeffrey Lipman
Brian M. Forde
Patrick N. A. Harris
Luregn J. Schlapbach
Lachlan Coin
Jason A. Roberts
Adam D. Irwin
Publication date: 13-03-2024
Publisher: Springer Berlin Heidelberg
Keywords: Antibiotic
Septicemia
Septicemia
Published in: Intensive Care Medicine / Issue 4/2024
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-024-07353-3

At a glance: The STEP trials

Springer Medicine

Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2024

Bedside-available strategies to minimise P-SILI and VILI during ARDS

Consistency of data reporting in fluid responsiveness studies in the critically ill setting: the CODEFIRE consensus from the Cardiovascular Dynamic section of the European Society of Intensive Care Medicine

Caring for frail patients in the ICU: a multidimensional approach

Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)

Knowing the ropes of vasopressor dosing: a focus on norepinephrine

Beauty, the beautician and empathy in the intensive care unit